Biosimilar Newsletter Archive

31. 09.29.22 -- EMA Releases Statement Supporting Biosimilar Interchangeability In EU 9/29/2022
    09/29/22 Biosimilar Development Newsletter
32. 09.22.22 -- A CTO's Journey Into Continuous Biomanufacturing 9/22/2022
    09/22/22 Biosimilar Development Newsletter
33. 09.16.22 -- How Updated FDA Guidance Impacts Component Selection 9/16/2022

    09/16/22 Biosimilar Development Newsletter

34. 09.15.22 -- De-Risking Biosimilar Development With A Suitable Autoinjector 9/15/2022
    09/15/22 Biosimilar Development Newsletter
35. 09.14.22 -- Biopharma Leaders Address Resilient Biomanufacturing Capacity Needs 9/14/2022

    09/14/22 Biosimilar Development Newsletter

36. 09.12.22 -- How Biopharma Leaders Are Pursuing Funding, Advocacy, And Regulatory Convergence 9/12/2022

    09/12/22 Biosimilar Development Newsletter

37. 09.08.22 -- Listen Now: Vaxxinity's Biologic Revolution, Best Practices for Partnering with a CDMO, and more! 9/8/2022
    09/08/22 Biosimilar Development Newsletter
38. 09.08.22 -- FDA Seeks Comments on Remote Regulatory Assessments 9/8/2022
    09/08/22 Biosimilar Development Newsletter
39. 09.07.22 -- A Guide To CDMO Selection 9/7/2022
    09/07/22 Biosimilar Development Newsletter
40. 09.01.22 -- Liposomal And Nanoparticle Technology At Pfizer Melbourne 9/1/2022
    09/01/22 Biosimilar Development Newsletter